Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705336 | 1.00 | EPHX2 (0.53) | EPHX2CTSSCTSKCTSLCTSB | |
| SCHEMBL10629248 | 0.91 | CTSS (0.52) | EPHX2CTSSCTSKCTSLCTSB | |
| SCHEMBL9797934 | 0.87 | CTSL (0.57) | CTSSCTSKCTSLCTSBIDO1 | |
| SCHEMBL10633866 | 0.85 | CTSL (0.50) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL6454981 | 0.85 | CTSL (0.50) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL8695509 | 0.83 | IDO1 (0.41) | CTSSCTSKCTSLCCKARCCKBR | |
| SCHEMBL11030896 | 0.82 | ACE (0.59) | EPHX2CTSSCTSKCTSLCTSB | |
| SCHEMBL27616185 | 0.82 | ACE (0.59) | EPHX2CTSSCTSKCTSLCTSB | |
| SCHEMBL8577285 | 0.81 | CTSL (0.46) | CTSSCTSKCTSLCTSBIDO1 | |
| SCHEMBL10631067 | 0.81 | CTSL (0.46) | CTSSCTSKCTSLCTSBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | EPHX2 2608/4885CTSS 1908/4885CTSK 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.